Caedo Oncology AS

Caedo Oncology AS is a biotechnology startup based in Norway, founded in 2020. The company's slogan, "We create improved treatment options for cancer patients through unique immunotherapy opportunities," embodies its focus on cancer immunotherapy. Caedo Oncology envisions being a leader in cancer immunotherapy through the development of novel monoclonal antibodies that induce programmed cell death in cancer cells. This approach marks a significant departure from traditional cancer treatment, which often targets both healthy and cancerous cells. Recognizing the limitations of cytotoxic treatments, the company aims to leverage advances in immunotherapy to selectively target cancer cells, offering new avenues for patient care. Its mission is underscored by the development of monoclonal antibody-based therapy strategies that activate distinctive pathways for cell death in cancer cells. These strategies are the result of research conducted at Oslo University Hospital and demonstrate Caedo Oncology's commitment to pioneering advancements in cancer treatment. Moreover, the recent Venture Round investment at 01 January 2023 from Farvatn Venture signifies external validation of Caedo Oncology's innovative approach to cancer immunotherapy. As a promising player in the intersection of biotechnology and healthcare, Caedo Oncology AS is poised to make a notable impact on cancer treatment through its focus on immunotherapy and targeted cell death pathways.